WO2009124755A1 - Composés à nouvelles utilisations médicales et procédés d'identification de ces composés - Google Patents
Composés à nouvelles utilisations médicales et procédés d'identification de ces composés Download PDFInfo
- Publication number
- WO2009124755A1 WO2009124755A1 PCT/EP2009/002620 EP2009002620W WO2009124755A1 WO 2009124755 A1 WO2009124755 A1 WO 2009124755A1 EP 2009002620 W EP2009002620 W EP 2009002620W WO 2009124755 A1 WO2009124755 A1 WO 2009124755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally substituted
- cycloalkyl
- hydrogen
- heterocycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 270
- 238000000034 method Methods 0.000 title claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 177
- 201000010099 disease Diseases 0.000 claims abstract description 93
- 238000011282 treatment Methods 0.000 claims abstract description 92
- 208000035475 disorder Diseases 0.000 claims abstract description 84
- 230000002265 prevention Effects 0.000 claims abstract description 75
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 32
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000001387 anti-histamine Effects 0.000 claims abstract description 27
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims abstract description 20
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims abstract description 20
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims abstract description 15
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims abstract description 15
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims abstract description 12
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims abstract description 12
- 229940121891 Dopamine receptor antagonist Drugs 0.000 claims abstract description 11
- 239000003420 antiserotonin agent Substances 0.000 claims abstract description 10
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002336 estazolam Drugs 0.000 claims abstract description 8
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims abstract description 7
- 208000001871 Tachycardia Diseases 0.000 claims abstract description 7
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 7
- 230000006794 tachycardia Effects 0.000 claims abstract description 7
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 claims abstract description 6
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 279
- 239000001257 hydrogen Substances 0.000 claims description 279
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 270
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 267
- 125000000217 alkyl group Chemical group 0.000 claims description 260
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 253
- 125000001072 heteroaryl group Chemical group 0.000 claims description 230
- 239000003814 drug Substances 0.000 claims description 219
- 229940079593 drug Drugs 0.000 claims description 210
- 125000003342 alkenyl group Chemical group 0.000 claims description 205
- 125000000304 alkynyl group Chemical group 0.000 claims description 198
- 125000003118 aryl group Chemical group 0.000 claims description 185
- 230000000694 effects Effects 0.000 claims description 131
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 102
- 229910052736 halogen Inorganic materials 0.000 claims description 93
- 150000002367 halogens Chemical group 0.000 claims description 93
- 125000002723 alicyclic group Chemical group 0.000 claims description 90
- 229910052760 oxygen Inorganic materials 0.000 claims description 67
- 229910052717 sulfur Inorganic materials 0.000 claims description 65
- 239000000126 substance Substances 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 53
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 48
- 125000003545 alkoxy group Chemical group 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 46
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 230000001225 therapeutic effect Effects 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 208000026935 allergic disease Diseases 0.000 claims description 16
- 230000007815 allergy Effects 0.000 claims description 16
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 13
- 208000028017 Psychotic disease Diseases 0.000 claims description 12
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 12
- 238000011524 similarity measure Methods 0.000 claims description 12
- 229960004157 rabeprazole Drugs 0.000 claims description 11
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 10
- 208000028185 Angioedema Diseases 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000024780 Urticaria Diseases 0.000 claims description 10
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 238000004422 calculation algorithm Methods 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 5
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 5
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 5
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004010 zaleplon Drugs 0.000 claims description 5
- 108091007265 Dopamine D2-Like Receptors Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 229960005339 acitretin Drugs 0.000 claims description 4
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 4
- 229960003608 clomifene Drugs 0.000 claims description 4
- 229960001066 disopyramide Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960004125 ketoconazole Drugs 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 4
- 229960002876 tegaserod Drugs 0.000 claims description 4
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 3
- 206010067484 Adverse reaction Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
- 208000014311 Cushing syndrome Diseases 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 230000006838 adverse reaction Effects 0.000 claims description 3
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 3
- 229960001803 cetirizine Drugs 0.000 claims description 3
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002001 ethionamide Drugs 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 229960003088 loratadine Drugs 0.000 claims description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229960000820 zopiclone Drugs 0.000 claims description 3
- IKBKZGMPCYNSLU-UHFFFAOYSA-N 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine Chemical compound C1=C(OC)C=C2C(C=NNC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-UHFFFAOYSA-N 0.000 claims description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- 206010001497 Agitation Diseases 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000000810 Separation Anxiety Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000001288 gastroparesis Diseases 0.000 claims description 2
- 201000003995 melancholia Diseases 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 2
- 229960001918 tiagabine Drugs 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- -1 ethyl methyl Chemical group 0.000 description 378
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 70
- 239000000460 chlorine Substances 0.000 description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 49
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 43
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 42
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 40
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 40
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 40
- 229910052801 chlorine Inorganic materials 0.000 description 38
- 229910052794 bromium Inorganic materials 0.000 description 37
- 229910052731 fluorine Inorganic materials 0.000 description 37
- 229910052740 iodine Inorganic materials 0.000 description 37
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 30
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 25
- 230000006870 function Effects 0.000 description 25
- 230000027455 binding Effects 0.000 description 22
- 239000003596 drug target Substances 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 19
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 18
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 18
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 18
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 18
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 18
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 18
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 18
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 18
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 18
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 18
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 18
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 18
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 18
- 125000002883 imidazolyl group Chemical group 0.000 description 18
- 125000001041 indolyl group Chemical group 0.000 description 18
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 18
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 18
- 125000001786 isothiazolyl group Chemical group 0.000 description 18
- 125000000842 isoxazolyl group Chemical group 0.000 description 18
- 125000001624 naphthyl group Chemical group 0.000 description 18
- 125000002971 oxazolyl group Chemical group 0.000 description 18
- 125000003373 pyrazinyl group Chemical group 0.000 description 18
- 125000003226 pyrazolyl group Chemical group 0.000 description 18
- 125000004076 pyridyl group Chemical group 0.000 description 18
- 125000000714 pyrimidinyl group Chemical group 0.000 description 18
- 125000000168 pyrrolyl group Chemical group 0.000 description 18
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 18
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 18
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 18
- 125000000335 thiazolyl group Chemical group 0.000 description 18
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 17
- 125000002541 furyl group Chemical group 0.000 description 17
- 125000001544 thienyl group Chemical group 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- DFVKOWFGNASVPK-BWHPXCRDSA-N [cyano-(4-phenoxyphenyl)methyl] (1s,3s)-3-[(z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](\C=C(/Cl)C(F)(F)F)[C@@H]1C(=O)OC(C#N)C(C=C1)=CC=C1OC1=CC=CC=C1 DFVKOWFGNASVPK-BWHPXCRDSA-N 0.000 description 7
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 6
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229960003530 donepezil Drugs 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 5
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 2
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010002064 Anaemia macrocytic Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 0 CC(*)(*)C(OC(CC1C2C3*2)*(*)CC3*1(**)O)=O Chemical compound CC(*)(*)C(OC(CC1C2C3*2)*(*)CC3*1(**)O)=O 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 201000006437 macrocytic anemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
- 229960001360 zolmitriptan Drugs 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- PBJUNZJWGZTSKL-INIZCTEOSA-N Cc1c(C(c2c(C)cc[s]2)=CCCN(CCC2)C[C@H]2C(O)=O)[s]cc1 Chemical compound Cc1c(C(c2c(C)cc[s]2)=CCCN(CCC2)C[C@H]2C(O)=O)[s]cc1 PBJUNZJWGZTSKL-INIZCTEOSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100029808 D(3) dopamine receptor Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101710107142 Dopamine receptor 2 Proteins 0.000 description 1
- 101710107136 Dopamine receptor 3 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 102100031274 Translocator protein Human genes 0.000 description 1
- 101710166801 Translocator protein Proteins 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940097222 agent acting on arteriolar smooth muscle Drugs 0.000 description 1
- 229940030613 agent acting on the renin-angiotensin system Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940029993 anabolic agent for systemic use Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940030226 antianemic preparations Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960001864 antidiarrheal microorganism Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030993 antifungals for dermatological use Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 229940029970 bile and liver therapy drug Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940030227 blood substitutes and perfusion solutions Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940097228 centrally acting antiadrenergic agent Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960004627 drug for functional gastrointestinal disorders Drugs 0.000 description 1
- 229940069429 drug for peptic ulcer and gastro-oesophageal reflux disease (gord) Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 229940037394 electrolytes with carbohydrate Drugs 0.000 description 1
- 229960001115 emollients and protectives Drugs 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229940097226 ganglion-blocking antiadrenergic agent Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000017482 infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940069496 intestinal adsorbents Drugs 0.000 description 1
- 229940069498 intestinal antiinfectives Drugs 0.000 description 1
- 229940069495 intestinal antiinflammatory agent Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940030627 lipid modifying agent Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002121 other alimentary tract and metabolism product in atc Drugs 0.000 description 1
- 229960004218 other antidiarrheals in atc Drugs 0.000 description 1
- 229940097237 other cardiac preparations in atc Drugs 0.000 description 1
- 229960004835 other hematological agent in atc Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940097224 peripherally acting antiadrenergic agent Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940030995 preparations for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical compound [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical class [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960001957 stomatological preparations Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229940097239 vasodilators used in cardiac diseases Drugs 0.000 description 1
- 229940030608 vasoprotectives Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Definitions
- the present invention relates to a method for identifying a novel medical indication of a pharmaceutically active compound.
- the invention further provides novel medical indications for several pharmaceutically active compounds.
- compounds are provided for the prevention and treatment of a disease or disorder treatable with a serotonin-norepinephrine reuptake inhibitor (SNRI), a serotonin receptor antagonist, an estazolam, a dopamine receptor antagonist, a dopamine receptor agonist, an L-type calcium channel blocker, a selective estrogen receptor modulator (SERM), an antihistamine.
- SNRI serotonin-norepinephrine reuptake inhibitor
- SERM selective estrogen receptor modulator
- an antihistamine also provided is a pharmaceutically active compound for the prevention or treatment of tachycardia.
- NRIs Norepinephrine reuptake inhibitors
- NARIs noradrenaline reuptake inhibitors
- ADHD attention-deficit hyperactivity disorder
- depression is useful sedatives, anxiolytics, sympathomimetics, and anticholinergics.
- NRIs can further be used to treat chronic fatigue syndrome, chronic pain and migraine's.
- Serotonin-norepinephrine reuptake inhibitors are a class of antidepressants used in the treatment of clinical depression and other affective disorders. They are also sometimes used to treat anxiety disorders, obsessive-compulsive disorder, attention deficit hyperactivity disorder (ADHD) and chronic neuropathic pain. They act upon two neurotransmitters in the brain that are known to play an important part in mood, namely, serotonin and norepinephrine. This can be contrasted with the more widely-used selective serotonin reuptake inhibitors (SSRIs), which act only on serotonin.
- SSRIs selective serotonin reuptake inhibitors
- Serotonin (5-hydroxytryptamine, or 5-HT) is a monoamine neurotransmitter synthesized in serotonergic neurons in the central nervous system (CNS) and enterochromaffin cells in the gastrointestinal tract of animals including humans. Serotonin is also found in many mushrooms and plants, including fruits and vegetables. Serotonin receptor antagonists are important antiemetic agents. They are particularly important in treating the nausea and vomiting that occur during anticancer chemotherapy using cytotoxic drugs. Another application is in treatment of post-operative nausea and vomiting. Applications to the treatment of depression and other mental and psychological conditions have also been investigated with some positive results. Serotonin receptor antagonists can also be used to treat intestinal pathologies or a psychosis.
- Estazolam (marketed under the brand names ProSom, Eurodin) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Estazolam is an intermediate-acting benzodiazepine. It is commonly prescribed for short-term treatment of insomnia.
- a dopamine antagonist is a drug which blocks dopamine receptors by receptor antagonism.
- dopamine receptors There are five types of dopamine receptors in the human body; they are found in the brain, peripheral nervous system, blood vessels, and the kidney).
- Dopamine receptor antagonist preferably a D2-like dopamine receptor antagonist find applications in the treatment of diseases such as psychosis, nausea, depression, Parkinson's Disease (depending on the patient's background) and migraine.
- Dopamine receptor agonist can be used to treat, for example, Parkinson's disease, pars intermedia hyperplasia or Equine Cushing's Syndrome (ECS).
- ECS Equine Cushing's Syndrome
- L-type calcium channel blockers can be used to treat hypertension, angina pectoris, cardiac arrhythmia and a headache.
- Calcium channel blockers work by blocking L-type voltage- gated calcium channels (VGCCs) in muscle cells of the heart and blood vessels. This prevents calcium levels from increasing as much in the cells when stimulated, leading to less muscle contraction.
- VGCCs voltage- gated calcium channels
- a decrease in calcium available for each beat results in a decrease in cardiac contractility.
- vasodilation In blood vessels, a decrease in calcium results in less contraction of the vascular smooth muscle and therefore an increase in blood vessel diameter, a phenomenon called vasodilation.
- Vasodilation decreases total peripheral resistance, while a decrease in cardiac contractility decreases cardiac output. Since blood pressure is in part determined by cardiac output and peripheral resistance, blood pressure drops.
- SERMs Selective Estrogen Receptor Modulators
- Their mode of action may be different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues.
- SERMs can be used to treat, for example, breast cancer, prostate cancer and for the treatment of serious side effects of androgen deprivation therapy.
- a histamine antagonist is an agent which serves to inhibit the release or action of histamine.
- Antihistamine can be used to describe any histamine antagonist, but it is usually reserved for the classical antihistamines that act upon the Hl histamine receptor.
- Histamine antagonist can be used to treat, for example, allergy such as hay fever, angioedema, and urticaria.
- Tachycardia refers to rapid beating of the heart. By convention it defined as a heart rate greater than 100 beats per minute in adults. Treatment of tachycardia is usually directed at chemical conversion using antiarrythmics.
- An antidepressant is a psychiatric medication or other substance (nutrient or herb) used for alleviating depression or dysthymia ('milder' depression).
- MAOIs Drug groups known as MAOIs, tricyclics and SSRIs are particularly associated with the term. These medications are now amongst the drugs most commonly prescribed by medical psychologists, psychiatrists and general practitioners, and their effectiveness and adverse effects are the subject of many studies. Most antidepressants have a delayed onset of action and are usually taken over the course of weeks, months or years. They are generally considered distinct from stimulants, and drugs used for an immediate euphoric effect only are not generally considered antidepressants.
- agents which act as serotonin-norepinephrine reuptake inhibitor (SNRI), a serotonin receptor antagonist, a dopamine receptor antagonist, a dopamine receptor agonist, an L-type calcium channel blocker, a selective estrogen receptor modulator (SERM), an antihistamine or which act like the pharmaceutically active compound estazolam can be administered for the prophylaxis and treatment of above mentioned diseases.
- SNRI serotonin-norepinephrine reuptake inhibitor
- SERM selective estrogen receptor modulator
- the present invention provides as a first aspect the use of a compound having a structure according to formula I:
- X is O or S
- Z is in each instance CR 4 R 5 ; ni is an integer from 1 to 5; n 2 is an integer from 1 to 5; m is an integer from 0 to 4;
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a Serotonin-norepinephrine reuptake inhibitor (SNRI).
- SNRI Serotonin-norepinephrine reuptake inhibitor
- the invention further provides the use of a compound having a structure according to formula III:
- Y is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 , -NR 4 COR 5 , -NR 4 COR 5 , -NR 4 CONR 6 R 7 , -NR 5 SO 2 A, -COR 6 - SO 2 NR 6 R 7 , -00CR 4 and -CR 4 R 5 OH; R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a Serotonin-norepinephrine reuptake inhibitor (SNRI).
- SNRI Serotonin-norepinephrine reuptake inhibitor
- W is alkyl, -OR 6 ', -CR 4 R 5 OH, or -NR 6 'R 7 '; Z is in each instance CR 4 R 5 ;
- xv ⁇ is an integer from 1 to 5;
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted;
- R 8 is each individually selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a norepinephrine reuptake inhibitors (NRIs).
- NRIs norepinephrine reuptake inhibitors
- the invention further provides the use of a compound having a structure according to formula VII:
- X is in each instance O or S; X' is in each instance O or S; Y is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted; R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted; R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a psychosis and/or a disease or disorder treatable with an antihistamine.
- the invention further provides the use of a compound having a structure according to formula IX:
- A is in each instance S, O or NR ';
- X is O or S;
- Z is in each instance CR 4 R 5 ;
- m is an integer from 0 to 4;
- ni is an integer from 1 to 5;
- n 2 is an integer from 1 to 5;
- R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R- is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R > * 4' and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl and heteroaryl; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 9 is in each instance independently selected from the group consisting of hydrogen,
- -OOCR 4 and -CR 4 R 5 OH;- R 10 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of disease or disorder treatable with a serotonin receptor antagonist, preferably a 5-HT2 type serotonin receptor antagonist.
- the invention further provides the use of a compound having a structure according to formula XI:
- B is C or N
- E is C or N
- X is O or S; if A is S then X is O; ml is an integer from O to 6; m2 is an integer from O to 3; m3 is an integer from O to 3; n 3 is an integer from 1 to 3;
- 1I 4 is an integer from 1 to 3;
- Y is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 ,
- Y' is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 ,
- Y is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 ,
- Z is in each instance CR 4 R 5 ;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein the bond indicated by the dashed line may be present
- the invention further provides the use of a compound having a structure according to formula XIII:
- B is C or N; G is C or S; X is in each instance O or S; Z is in each instance CR 4 R 5 ; m is an integer from 0 to 3; n] is an integer from 1 to 5; n 2 is an integer from 1 to 5; R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a dopamine receptor antagonist, preferably a type D2-like dopamine receptor antagonist.
- the invention further provides the use of a compound having a structure according to formula XV:
- A is S, O or NR 6 ';
- X is O or S;
- Y is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- A is each independently selected from S, O or NR 6 ' ; Z is in each instance CR 4 R 5 ; ml is an integer from 0 to 3; m2 is an integer from O to 3; n is an integer from 1 to 5; R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein the bond indicated by the dashed line may be present or not; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a dopamine receptor agonist.
- the invention further provides the use of a compound having a structure according to formula XIX:
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is in each instance selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein each of the bonds indicated by the dashed line may be present or not; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an L-type calcium channel blocker.
- the invention further provides the use of a compound having a structure according to formula XXI:
- X is O or S; Z is in each instance CR 4 R 5 ; n is an integer from 1 to 5;
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted; and R 8 is in each instance selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of cancer and/or a disease or disorder treatable with a selective estrogen receptor modulator (SERM).
- SERM selective estrogen receptor modulator
- the invention further provides the use of a compound having a structure according to formula XXIII:
- XXIII wherein X is O or S; n is an integer from 1 to 5;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- the invention further provides the use of a compound having a structure according to formula XXV:
- XXV wherein ml is an integer from O to 5; m2 is an integer from 0 to 4; X is O or S; Y is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- Y' is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is in each instance selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein the bond indicated by the dashed line may be present or not; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- the invention further provides the use of a compound having a structure according to formula XXVII:
- m is an integer from O to 3; B is C or N; X is O or S; Y is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 ,
- R 3 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of tachycardia or a disease or disorder treatable with an antihistamine, for example an allergy such as hay fever, angioedema or urticaria.
- the invention further provides the use of a compound having a structure according to formula XXIX:
- X is O or S
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R x is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- the invention further provides the use of a compound having a structure according to formula XXXI:
- XXXI wherein ml is an integer from 0 to 2; m2 is an integer from 1 to 2; m3 is an integer from 0 to 4; Y is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 ,
- Y' is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- Y' ' is in each instance selected from the group consisting of hydrogen, halogen, -NO 2 , -CN,
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 11 is selected from the group consisting of hydrogen, -COR 12 , -CR 4 R 5 OH, alkyl, alkynyl and cycloalkyl; optionally substituted;
- R 12 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a depression and/or a disease or disorder treatable with an antihistamine.
- the invention further provides the use of a compound having a structure according to formula XXXIII:
- m is an integer between 0 and 2; B is in each instance C or N; X is O or S; Y is selected from the group consisting of hydrogen, halogen, -NO 2 , -CN, -OR 6 ,
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 11 is selected from the group consisting of hydrogen, -COR 12 , -CR 4 R 5 OH, alkyl, alkynyl and cycloalkyl; optionally substituted;
- R 12 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a depression and/or a disease or disorder treatable with an antihistamine.
- the invention further provides a method for identifying a novel medical indication of a pharmaceutically active compound comprising the steps:
- the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
- alkyl "heteroalkyl”, “cycloalkyl”, “heterocycloalkyl”, “alicyclic system”, “aryl”, “aralkyl”, “heteroaryl”, “heteroaralkyl”, "alkenyl”, “cycloalkenyl”, “alkynyl” and “optionally substituted” are provided.
- alkyl refers to a saturated straight or branched carbon chain.
- the chain comprises from 1 to 10 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 e.g. methyl, ethyl methyl, ethyl, propyl, wo-propyl, butyl, wo-butyl, tert-butyl, pentyl or hexyl, heptyl, or octyl.
- Alkyl groups are optionally substituted.
- heteroalkyl refers to a saturated straight or branched carbon chain.
- the chain comprises from 1 to 9 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 e.g. methyl, ethyl, propyl, wo-propyl, butyl, wo-butyl, sec-butyl, tert-butyl, pentyl or hexyl, heptyl, octyl, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms.
- the heteroatoms are selected from O, S, and N, e.g.
- Heteroalkyl groups are optionally substituted.
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc.
- cycloalkyl and “heterocycloalkyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof.
- heterocycloalkyl preferably refers to a saturated ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a saturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a saturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms.
- Cycloalkyl and “heterocycloalkyl” groups are optionally substituted. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
- Preferred examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, spiro[3,3]heptyl, spiro[3,4]octyl, spiro[4,3]octyl, spiro[3,5]nonyl, spiro[5,3]nonyl, spiro[3,6]decyl, spiro[6,3]decyl, spiro[4,5]decyl, spiro[5,4]decyl, bicyclo[4.
- heterocycloalkyl examples include l-(l,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3- piperidinyl, 4-morpholinyl, 3-morpholinyl, 1,8 diaza-spiro-[4,5] decyl, 1,7 diaza-spiro-[4,5] decyl, 1,6 diaza-spiro-[4,5] decyl, 2,8 diaza-spiro[4,5] decyl, 2,7 diaza-spiro[4,5] decyl, 2,6 diaza-spiro[4,5] decyl, 1,8 diaza-spiro-[5,4] decyl, 1,7 diaza-spiro-[5,4] decyl, 2,8 diaza-spiro- [5,4] decyl, 2,7 diaza-spiro[5,4] decyl, 3,8 diaza-spiro[5,4] decyl, 3,7 diaza-
- alicyclic system refers to mono, bicyclic, tricyclic or polycyclic version of a cycloalkyl or heterocycloalkyl comprising at least one double and/or triple bond.
- an alicyclic system is not aromatic or heteroaromatic, i.e. does not have a system of conjugated double bonds/free electron pairs.
- the number of double and/or triple bonds maximally allowed in an alicyclic system is determined by the number of ring atoms, e.g. in a ring system with up to 5 ring atoms an alicyclic system comprises up to one double bond, in a ring system with 6 ring atoms the alicyclic system comprises up to two double bonds.
- the "cycloalkenyl" as defined below is a preferred embodiment of an alicyclic ring system.
- Alicyclic systems are optionally substituted.
- aryl preferably refers to an aromatic monocyclic ring containing 6 carbon atoms, an aromatic bicyclic ring system containing 10 carbon atoms or an aromatic tricyclic ring system containing 14 carbon atoms. Examples are phenyl, naphtyl or anthracenyl. The aryl group is optionally substituted.
- aralkyl refers to an alkyl moiety, which is substituted by aryl, wherein alkyl and aryl have the meaning as outlined above. An example is the benzyl radical.
- the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g.
- aralkyl group is optionally substituted at the alkyl and/or aryl part of the group.
- heteroaryl preferably refers to a five or six-membered aromatic monocyclic ring wherein at least one of the carbon atoms are replaced by 1, 2, 3, or 4 (for the five membered ring) or 1, 2, 3, 4, or 5 (for the six membered ring) of the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 8, 9, 10, 11 or 12 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 13, 14, 15, or 16 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S.
- Examples are oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3- triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazoyl, benzothiazolyl, 1,2-benzisothiazolyl,
- heteroarylkyl refers to an alkyl moiety, which is substituted by heteroaryl, wherein alkyl and heteroaryl have the meaning as outlined above.
- An example is the 2- alklypyridinyl, 3-alkylpyridinyl, or 2-methylpyridinyl.
- the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g.
- heteroaralkyl group is optionally substituted at the alkyl and/or heteroaryl part of the group.
- alkenyl and cycloalkenyl refer to olefinic unsaturated carbon atoms containing chains or rings with one or more double bonds. Examples are propenyl and cyclohexenyl.
- the alkenyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g.
- cycloalkenyl ring comprises from 3 to 14 carbon atoms, i.e. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, e.g.
- alkynyl refers to unsaturated carbon atoms containing chains or rings with one or more triple bonds.
- An example is the propargyl radical.
- the alkynyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethynyl, 1-propynyl, 2- propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, hexynyl, pentynyl, octynyl.
- substituents e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substituents which are in each instance independently selected from the group consisting of halogen, in particular F, Cl, Br or I; -R', -NO 2 , -CN, -OR 1 , -NR'R", -COOR', -CONR'R", -NR"'COR"' ⁇ -NR'"COR”", -NR'"CONR'R", -NR"SO 2 A, -COR'”; -SO 2 NR 5 R", -OOCR'", -CR'"R”"OH, R'"OH, and -E;
- R' and R" is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, or heterocycloalkyl;
- R'" and R"" is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR'R";
- E is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkoxy, alkoxyalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- the term "a compound according to the invention” refers to a compound according to any of formulas I through XXXTV including all preferred respective embodiment
- drug and pharmaceutically active compound(s) are used interchangeably.
- unexpected activities derived from off-targets are usually unwanted and harmful, they can sometimes be beneficial. As will be explained herein, they can, for example, lead to new therapeutic indications for existing, marketed drugs.
- the inventors of the present invention have established a computer implemented method to explore the vast amount of human phenomenological data generated from the use of marketed drugs, namely side effects, to infer molecular activities of drugs that are not implicit by their chemical similarity or the sequence similarity of their known targets. Simply making an "educated guess" that two compounds which have closely related side-effects will also share a common therapeutic target is prone to result in too many false predictions. Therefore, the present inventors have invested in refining and optimizing a complex computer implemented method which considers a plurality of data dependencies and which integrates the data by elaborous filtering and weighing steps as will be described herein. Unexpectedly, the optimized computer
- program was capable of identifying several hundred pairs of compounds which (a) merely have low chemical similarity and are, thus, structurally different, which (b) the prior art has classified in different therapeutic categories, which (c) were previously not known to share the same therapeutical target and which (d) are not related by the amino acid sequence similarity of their respective therapeutic target proteins. Importantly, for several of these identified compounds it was shown in "wet-lab” experiments that the respective drug pairs indeed share the same therapeutic target. In the following, novel medical indications will be provided for known compounds.
- the disorder or disease treatable with the respective compound according to the invention is frequently defined herein as a disorder or disease which is currently treated with a different pharmaceutical compound or any different pharmaceutical compound that belongs to a generic class of medicaments.
- the invention provides the use of a compound having a structure according to formula I:
- X is O or S; preferably X is O Z is in each instance CR 4 R 5 ; ni is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably nl is 2; n 2 is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n2 is 1 ; m is an integer from 0 to 4; i.e.
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a Serotonin-norepinephrine reuptake inhibitor (SNRI).
- SNRI Serotonin-norepinephrine reuptake inhibitor
- SNRI Serotonin-norepinephrine reuptake inhibitor
- At least one of the respective substituents of the compound according to formula I is defined as follows:
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl,
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- R 4 and R 5 is preferably each independently selected from the group consisting of hydrogen, alkyl (in particular Ci-C ⁇ alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 , or Ce alkyl, preferably methyl, ethyl, propyl, wo-propyl, butyl, wo-butyl, tert-butyl, pentyl or hexyl), alkenyl and alkynyl; optionally substituted.
- alkyl in particular Ci-C ⁇ alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 , or Ce alkyl, preferably methyl, ethyl, propyl, wo-propyl, butyl, wo-butyl, tert-butyl, pentyl or hexyl
- alkenyl and alkynyl optionally substituted.
- nl is 2, n2 is 1,
- the compound according to structure I has a structure according to formula II (cetirizine):
- the invention further provides the use of a compound having a structure according to formula III:
- n is an integer from 0 to 9; i.e. an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; preferably m is 0;
- X is O or S; preferably X is O;
- Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I),
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen,
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a Serotonin-norepinephrine reuptake inhibitor (SNRI).
- SNRI Serotonin-norepinephrine reuptake inhibitor
- At least one of the respective substituents of the compound according to formula III is defined as follows:
- Y is preferably selected from the group consisting of hydrogen, -OR 6 , -NR 6 R 7 and -COOR 6 ;
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1 ,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl,
- R is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1 ,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl,
- R 6 and R 7 is preferably each independently selected from the group consisting of hydrogen, alkyl
- Ci-C ⁇ alkyl e.g. C 1 , C 2 , C 3 , C 4 , C 5 , or Ce alkyl, preferably methyl, ethyl, propyl, /so-propyl, butyl, wo-butyl, tert-butyl, pentyl or hexyl
- alkenyl alkynyl, cycloalkyl, heterocycloalkyl (C 3 -C 14 -heterocycloalkyl, e.g.
- 2,1-benzisoxazolyl benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl, 1,2,3-benzotriazinyl, or 1 ,2,4-benzotriazinyl), and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted; and most preferably R 6 and/or R 7 is hydrogen; and
- R 6 ' and R 7 ' is preferably alkyl (in particular Ci-C 6 alkyl, e.g. Ci, C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, /s ⁇ -propyl, butyl, /so-butyl, tert-butyl, pentyl or hexy ⁇ ); optionally substituted.
- X is O
- R 6 ' and R 7 ' is methyl and m is zero and preferably Y is -OH.
- the compound according to structure III has a structure according to formula IV (tiotropium):
- the invention further provides the use of a compound having a structure according to formula V:
- W is alkyl, -OR 6 ', -CR 4 R 5 OH, or -NR 6 'R 7 '; Z is in each instance CR 4 R 5 ;
- n! is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n ⁇ is 2;
- R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted; R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted; R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a heterocycloalkyl; optionally substituted; R 8 is each individually selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof
- At least one of the respective substituents of the compound according to formula V is defined as follows: W is preferably -NR 6 'R 7 ';
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- R 6 ' and R 7 ' is preferably each independently selected from the group consisting of hydrogen and alkyl (in particular Ci-C 6 alkyl, e.g. Ci, C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, /so-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R 8 is preferably hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- nl is 2
- W is -NH 2
- R 8 is isopropyl.
- the compound according to structure V has a structure according to formula VI (disopyramide):
- a compound according to formula V or VI can be used for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- a compound according to any of formulas I - VI can be used for the prevention or treatment of a depression and/or an anxiety disorder.
- the invention further provides the use of a compound having a structure according to formula VII:
- X is in each instance O or S; preferably X is O; X' is in each instance O or S; preferably X' is O; Y is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 , -NR 4 COR 5 , -NR 4 COR 5 , -NR 4 CONR 6 R 7 , -NR 5 SO 2 A, -COR 6 , -SO 2 NR 6 R 7 , -OOCR 4 and -CR 4 R 5 OH;
- halogen preferably F, Cl, Br or I
- Z is in each instance CR 4 R 5 ; n is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n is 1; In 1 is an integer between O and 3; i.e. an integer selected from O, 1, 2 or 3; preferably mi is O; m 2 is an integer between O and 3; i.e.
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a psychosis and/or a disease or disorder treatable with an antihistamine such as, for example, an allergy.
- At least one of the respective substituents of the compound according to formula VII is defined as follows:
- Y is preferably in each instance selected from the group consisting of -OR 6 , -NR 6 R 7 and -COOR 6 ; and is most preferably -OH;
- R 2 is preferably cycloalkyl or heterocycloalkyl (C 3 -C 14 -heterocycloalkyl, e.g. C 3 , C 4 , C5, C 6 ,
- R 4 and R 5 is preferably each independently selected from hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted;
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- R 6 and R 7 is preferably each independently selected from hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and R 8 is preferably alkyl (in particular C1-C6 alkyl, e.g.
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- the compound according to structure VII has a structure according to formula VIII (doxorubicin):
- the invention further provides the use of a compound having a structure according to formula IX:
- A is in each instance S, O or NR 6 '; preferably A is O; X is O or S; preferably X is O; Z is in each instance CR 4 R 5 ; m is an integer from O to 4; i.e. an integer selected from 0, 1 , 2, 3 or 4; preferably m is 0; ni is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n t is 1; n 2 is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n 2 is 1; R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl and heteroaryl; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 9 is in each instance independently selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 ,
- R 10 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of disease or disorder treatable with a serotonin receptor antagonist, preferably a 5-HT2 type serotonin receptor antagonist and most preferably a 5-HT2C type serotonin receptor antagonist.
- a serotonin receptor antagonist preferably a 5-HT2 type serotonin receptor antagonist and most preferably a 5-HT2C type serotonin receptor antagonist.
- At least one of the respective substituents of the compound according to formula IX is defined as follows:
- R 1 is preferably cycloalkyl or heterocycloalkyl (C 3 -C 14 -heterocycloalkyl, e.g. C 3 , C 4 , C 5 , C 6 ,
- C 7 , C 8 , C 9 , C 10 , Cn, Ci 2 , Cu or C ⁇ -heterocycloalkyl in particular piperidinyl, morpholinyl, 1 ,3-diazacyclohexanyl, 1,8 diaza-spiro-[4,5] decyl, 1,7 diaza-spiro-[4,5] decyl, 1,6 diaza-spiro-[4,5] decyl, 2,8 diaza-spiro[4,5] decyl, 2,7 diaza-spiro[4,5] decyl,
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- R 3 is preferably hydrogen or alkyl (in particular Ci-C 6 alkyl, e.g. Ci, C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, /so-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyt); optionally substituted;
- Ci-C 6 alkyl e.g. Ci, C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, /so-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyt
- R 4 and R 5 is preferably each independently selected from hydrogen or alkyl (in particular Ci-C 6 alkyl, e.g. Ci, C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, /so-propyl, butyl, wo-butyl, tert-butyl, pentyl or hexyt); optionally substituted; and
- R 10 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- the compound according to structure IX has a structure according to formula X (ketoconazole):
- a compound according to formula IX or X is used for the prevention or treatment of a psychosis and/or nausea.
- the invention further provides the use of a compound having a structure according to formula XI:
- A is S, O or NR 6' ; preferably A is O; B is C or N; preferably B is N; E is C or N; preferably E is C; X is O or S; if A is S then X is O; preferably X is O; ml is an integer from O to 6; i.e. an integer selected from O, 1, 2, 3, 4, 5 or 6; preferably ml is O; m2 is.an integer from 0 to 3; i.e. an integer selected from 0, 1, 2 or 3; preferably m2 is 1; m3 is an integer from 0 to 3; i.e.
- n 3 is an integer from 1 to 3; i.e. an integer selected from 1, 2 or 3; preferably n 3 is 2;
- Xi 4 is an integer from 1 to 3; i.e. an integer selected from 1, 2 or 3; preferably 11 4 is 2;
- Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I),
- Y' is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I),
- Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I),
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl (preferably C1-C6 alkyl, e.g.
- Y' is preferably selected from the group consisting of hydrogen, halogen (preferably F, Cl,
- R 4 and R 5 is preferably hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R 8 is preferably selected from the group consisting of alkyl (in particular Cl -C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, tert-butyl, pentyl or hexyl), alkenyl and alkynyl; optionally substituted.
- alkyl in particular Cl -C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, tert-butyl, pentyl or hexyl
- alkenyl and alkynyl optionally substituted.
- A is O
- X is O
- B is N
- E is C
- m 2 l
- In 3 O
- n 3 2
- Hi 1 O
- 11 4 2 and the bond indicated by the dashed line is present.
- the compound according to structure XI has a structure according to formula XII (loratadine):
- a compound according to formula XI or XII is used for the prevention or treatment of a disease or disorder selected from the group consisting of anxiety disorder, insomnia, agitation, a seizure, a muscle spasm and substance abuse-related disorder.
- the invention further provides the use of a compound having a structure according to formula XIII:
- B is C or N; preferably B is N; G is C or S; preferably G is S; X is in each instance O or S; preferably X is O; Z is in each instance CR 4 R 5 ;
- m is an integer from 0 to 3; i.e. an integer selected from 0, 1, 2 or 3; preferably m is 1;
- n ! is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n t is 3; n 2 is an integer from 1 to 5; i.e.
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR R ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a dopamine receptor antagonist, preferably a type D2-like dopamine receptor antagonist.
- At least one of the respective substituents of the compound according to formula XIII is defined as follows:
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1 -benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimid
- R 3 is preferably alkyl; optionally substituted
- R 4 and R 5 is preferably each independently selected from hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and R 8 is preferably selected from the group consisting alkyl (in particular C 1 -C6 alkyl, e.g.
- C 1 , C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl), alkenyl and alkynyl; optionally substituted.
- the compound according to structure XIII has a structure according to formula XIV (rabeprazole):
- a compound according to formula XIII or XIV is used for the prevention or treatment of a disease or disorder selected from the group consisting of psychosis, nausea, depression, Parkinson's disease and migraine.
- the invention further provides the use of a compound having a structure according to formula XV:
- m is an integer from 1 to 4; i.e. an integer selected from 1, 2, 3 or 4; preferably m is 1;
- A is S, O or NR 6 ' ; preferably A is S;
- X is O or S; preferably X is O;
- Y is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 , -NR 4 COR 5 , -NR 4 COR 5 ,
- R is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with Tegaserod (2-((5-Methoxy-lH-indol-3-yl)methylene)-N- penty lhydrazinecarboximidamide) .
- At least one of the respective substituents of the compound according to formula XV is defined as follows: Y is preferably in each instance selected from the group consisting of -OR 6 , -NR 6 R 7 and
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl,
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl,
- R 6 and R 7 is preferably each independently selected from the group consisting of hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- X is O
- A is S
- the compound according to structure XV has a structure according to formula XVI (raloxifene):
- a compound according to formula XV or XVI is used for the prevention or treatment of an intestinal pathology, for example gastric stasis or irritable bowel syndrome;
- the invention further provides the use of a compound having a structure according to formula XVII:
- A is each independently selected from S, O or NR 6 '; preferably A is S; Z is in each instance CR 4 R 5 ;
- In 1 is an integer from 0 to 3; i.e. an integer selected from 0, 1, 2 or 3; preferably In 1 is 1; m 2 is an integer from 0 to 3; i.e. an integer selected from 0, 1, 2 or 3; preferably m 2 is 1; n is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n is 2;
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein the bond indicated by the dashed line may be present or not; preferably the bond is present; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with a dopamine receptor agonist.
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl (C 3 -C 14 - heterocycloalkyl, e.g.
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), and alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; R 4 and R 5 is each independently selected from the group consisting of hydrogen and alkyl (in particular C1-C6 alkyl, e.g.
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R' 8 is hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- C1-C6 alkyl e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- the compound according to structure XVII has a structure according to formula XVIII (tiagabine):
- a compound according to formula XVII or XVIII is used for the prevention or treatment of a disease or disorder selected from the group consisting of Parkinson's disease, pars intermedia hyperplasia and Equine Cushing's Syndrome (ECS).
- a disease or disorder selected from the group consisting of Parkinson's disease, pars intermedia hyperplasia and Equine Cushing's Syndrome (ECS).
- the invention further provides the use of a compound having a structure according to formula XIX:
- n is an integer from 2 to 6; i.e. an integer selected from 2, 3, 4, 5 or 6; preferably n is 3; o is an integer from 0 to 4; i.e. an integer selected from 0, 1, 2, 3 or 4; preferably o is 0; X is in each instance O or S; preferably X is O;
- Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; optionally substituted;
- R 8 is in each instance selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and wherein each of the bonds indicated by the dashed line may be present or not; preferably the bond is present; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an L-type calcium channel blocker.
- At least one of the respective substituents of the compound according to formula XIX is defined as follows:
- R 3 is preferably hydrogen, halogen (preferably F, Cl, Br or I) or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted;
- halogen preferably F, Cl, Br or I
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- R 6 ' is preferably hydrogen or alkyl (in particular C 1 -C6 alkyl, e.g. C 1 , C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and R 8 is preferably hydrogen or alkyl (in particular C1-C6 alkyl, e.g.
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- n 3
- R 6 is methyl
- the compound according to structure XIX has a structure according to formula XX (vitamin Kl):
- a compound according to formula XIX or XX is used for the prevention or treatment of a disease or disorder selected from the group consisting of hypertension, angina pectoris, cardiac arrhythmia and a headache.
- the invention further provides the use of a compound having a structure according to formula XXI:
- X is O or S; preferably X is O; Z is in each instance CR 4 R 5 ; n is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably n is 1; R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted; R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl,
- At least one of the respective substituents of the compound according to formula XXI is defined as follows:
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1 ,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimid
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted;
- R 4 and R 5 is preferably each independently selected from hydrogen and alkyl (in particular Cl- C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso- propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted;
- alkyl in particular Cl- C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso- propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- R 6 and R 7 is preferably each independently selected from the group consisting of hydrogen and alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted;
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl
- R 6 ' and R 7 ' is preferably each independently selected from the group consisting of hydrogen and alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and R 8 is preferably alkyl (in particular C1-C6 alkyl, e.g.
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- n l
- R 6 and R 7 is methyl and X is O.
- the compound according to structure XXI has a structure according to formula XXII (Methadone):
- a compound according to formula XXI or XXII is used for the prevention or treatment of a disease or disorder selected from the group consisting of breast cancer, prostate cancer and for the treatment of serious side effects of androgen deprivation therapy.
- a disease or disorder selected from the group consisting of breast cancer, prostate cancer and for the treatment of serious side effects of androgen deprivation therapy.
- the disease is any form of cancer.
- the invention further provides the use of a compound having a structure according to formula XXIII:
- X is O or S; preferably X is O; n is an integer from 1 to 5; i.e. an integer selected from 1, 2, 3, 4 or 5; preferably nis 2;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; and if two R 3 substituents are on adjacent carbon atoms, they may together form a cycloalkyl, heterocycloalkyl or alicyclic system; optionally substituted;
- R ,3 J ' is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with treatable with an antihistamine.
- At least one of the respective substituents of the compound according to formula XXIII is defined as follows:
- R 3 is preferably selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), and alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; R 3' is preferably alkyl (in particular C1-C6 alkyl, e.g.
- C2, C3, C4, C5, or C6 alkyl preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R 8 is preferably alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- n 2 and X is O.
- the compound according to structure XXIII has a structure according to formula XXIV (acitretin):
- the invention further provides the use of a compound having a structure according to formula XXV:
- ml is an integer from O to 5; i.e. an integer selected from O, 1, 2, 3, 4 or 5; preferably ml is O; m2 is an integer from 0 to 4; i.e. an integer selected from 0, 1, 2, 3 or 4; preferably m2 is 0;
- X is O or S; preferably X is O; Y is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 , -NR 6 R 7 , -COOR 6 , -CONR 6 R 7 ,
- Y' is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is in each instance selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted and preferably substituted with -NR 6 R 7 ; and wherein the bond indicated by the dashed line may be present or not; preferably the bond is present; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- At least one of the respective substituents of the compound according to formula XXV is defined as follows:
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl,
- 1,2,5-thiadiazolyl pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1- benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl, 1,2,3-benzotriazinyl, or 1 ,2,4-benzotriazinyl); optionally substituted;
- R 3 is preferably halogen (preferably F, Cl, Br or I).
- R 8 is preferably alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- the compound according to structure XXV has a structure according to formula XXVI (clomiphene):
- the compound according to formula XXV or XXVI is comprised in a composition, which further comprises citrate.
- a compound according to formula XXV or XXVI is used for the prevention or treatment of an allergy such as hay fever, angioedema or urticaria.
- the invention further provides the use of a compound having a structure according to formula XXVII:
- m is an integer from O to 3; i.e. an integer selected from 0, 1 , 2 or 3; preferably m is 0; B is C or N; preferably B is N; X is O or S; preferably X is S; Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I),
- R 3 is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 6 ' and R 7 ' is each independently selected from the group consisting of hydrogen, alkyl, alkenyl or together form a
- At least one of the respective substituents of the compound according to formula XXVII is defined as follows:
- R 3 is preferably halogen (preferably F, Cl, Br or I) or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R 6 ' and R 7 ' is preferably hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- alkyl in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- the compound according to structure XXVII has a structure according to formula XXVIII (ethionamide):
- the invention further provides the use of a compound having a structure according to formula XXIX:
- X is O or S; preferably X is O;
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a disease or disorder treatable with an antihistamine.
- R 1 is preferably cycloalkyl or heterocycloalkyl (C 3 -C ]4 -heterocycloalkyl, e.g.
- Ci 2 , Ci 3 or C ⁇ -heterocycloalkyl in particular piperidinyl, morpholinyl, 1,3-diazacyclohexanyl, 1,8 diaza-spiro-[4,5] decyl, 1,7 diaza-spiro-[4,5] decyl, 1,6 diaza-spiro-[4,5] decyl, 2,8 diaza-spiro[4,5] decyl, 2,7 diaza-spiro[4,5] decyl, 2,6 diaza-spiro[4,5] decyl, 1,8 diaza-spiro-[5,4] decyl, 1,7 diaza-spiro-[5,4] decyl, 2,8 diaza-spiro-[5,4] decyl, 2,7 diaza-spiro[5,4] decyl, 3,8 diaza-spir
- R 2 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothienyl, 2- benzothienyl, lH-indazolyl, benzimidazoly
- R 8 is hydrogen, X is O and R 1 is optionally substituted with alkyl.
- the compound according to structure XXIX has a according to formula XXX (nateglinide):
- a compound according to formula XXIX or XXX is used for the prevention or treatment of an allergy such as hay fever, angioedema or urticaria.
- the invention further provides the use of a compound having a structure according to formula XXXI:
- ml is an integer from O to 2; i.e. an integer selected from 0, 1 or 2; preferably ml is 0; m2 is an integer from 1 to 2; i.e. an integer selected from 1 or 2; preferably m2 is 1 ; m3 is an integer from 0 to 4; i.e. an integer selected from 0, 1, 2, 3 or 4; preferably m3 is 0; Y is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- Y' is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- Y is in each instance selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 8 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and cycloalkyl; optionally substituted;
- R 11 is selected from the group consisting of hydrogen, -COR 12 , -CR 4 R 5 OH, alkyl, alkynyl and cycloalkyl; optionally substituted
- At least one of the respective substituents of the compound according to formula XXXI is defined as follows: Y' is preferably -NO 2 or -CN; R 8 is preferably hydrogen or alkyl (in particular C1-C6 alkyl, e.g. Cl, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted; and
- R 1 ' is preferably -COR 12 ; wherein R 12 is preferably alkyl (in particular C 1 -C6 alkyl, e.g. C 1 , C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl); optionally substituted.
- alkyl in particular C 1 -C6 alkyl, e.g. C 1 , C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl or hexyl
- R 12 is preferably alkyl (in particular C 1 -C6 alkyl, e.g. C 1 , C2, C3, C4, C5, or C6 al
- the compound according to structure XXXI has a according to formula XXXII (zaleplon):
- a compound according to formula XXXI or XXXII is used for the prevention or treatment of an allergy such as hay fever, angioedema or urticaria.
- the invention further provides the use of a compound having a structure according to formula XXXIII:
- m is an integer between 0 and 2; i.e. an integer selected from 0, 1 or 2; preferably m is 0; B is in each instance C or N; preferably B is N; X is O or S; preferably X is O;
- Y is selected from the group consisting of hydrogen, halogen (preferably F, Cl, Br or I), -NO 2 , -CN, -OR 6 ,
- R 1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, an alicyclic system, aryl and heteroaryl; optionally substituted;
- R 4 and R 5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, aralkyl, heteroaryl, and -NR 6 R 7 ; optionally substituted;
- R 6 and R 7 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl or together form a heteroaryl, and heterocycloalkyl; optionally substituted;
- R 11 is selected from the group consisting of hydrogen, -COR I2 ; -CR 4 R 5 OH, alkyl, alkynyl and cycloalkyl; optionally substituted;
- R 12 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and aralkyl; optionally substituted; or pharmaceutically acceptable salts thereof, for the prevention or treatment of a depression and/or a disease or disorder treatable with an antihistamine.
- R 1 is preferably aryl (in particular phenyl, naphthalenyl or anthracenyl), or heteroaryl (in particular furanyl, thienyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5- triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, be
- Ci 2 , Ci 3 or Ci 4 - heterocycloalkyl in particular piperidinyl, morpholinyl, 1,3-diazacyclohexanyl, 1,8 diaza-spiro-[4,5] decyl, 1,7 diaza-spiro-[4,5] decyl, 1,6 diaza-spiro-[4,5] decyl, 2,8 diaza- spiro[4,5] decyl, 2,7 diaza-spiro[4,5] decyl, 2,6 diaza-spiro[4,5] decyl, 1,8 diaza-spiro- [5,4] decyl, 1,7 diaza-spiro-[5,4] decyl, 2,8 diaza-spiro-[5,4] decyl, 2,7 diaza-spiro[5,4] decyl, 3,8 diaza-spiro- [5,4] decyl, 1,7 diaza-spiro-[5,4] decyl, 2,8 di
- R 11 is , wherein the asterisk indicates where the substitutent is attached to the O atom of formula (XXXIII) and wherein n is an integer between 0 and 2; i.e. an integer selected from 0, 1 or 2; preferably n is 0; and Y and has the above outlined meaning.
- the compound according to structure XXXIII has a structure according to formula XXXIV (zopiclone):
- a compound according to formula XXXIII or XXXIV is used for the prevention or treatment of an allergy such as hay fever, angioedema or urticaria.
- a compound of the invention is used for for the prevention or treatment of a depression, then it is preferred that the depression is selected from the group consisting of clinical depression, melancholic depression, atypical depression, psychotic depression and postnatal depression. If a compound of the invention is used for for the prevention or treatment of an anxiety disorder, then it is preferred that the anxiety disorder is selected from the group consisting of panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder and separation anxiety.
- a compound of the invention is used for for the prevention or treatment of a psychosis, then it is preferred that the psychosis is selected from the group consisting of schizophrenia, bipolar disorder, mania and delusional disorder.
- Several compounds described herein are useful to treat an allergy. These compounds are preferably used to treat an allergy selected from the group consisting of: allergic rhinitis, asthma, atopic eczema, anaphylaxis, an insect venom-induced allergy, a drug induced allergy, a food- induced allergy and a multiple allergy disorder.
- table 3 lists pairs of pharmaceuticals which share the same therapeutic target.
- a pharmaceutical listed in column “Drug 1 (PugChem ID)” can also be used for the therapy of a disease or disorder that is generally treatable which a respective compound listed in the column “Drug 2 (PugChem ID)” of table 3.
- a pharmaceutical listed in column “Drug 2 (PugChem ID)” can be used for the therapy of a disease or disorder that is generally treatable which a respective compound listed in the column “Drug 1 (PugChem ID)”.
- a compound listed in table 3 under "Drug 1 (PugChem ID)" for the prevention or treatment of a medical indication as indicated under “T. Cat Drug2” and encoded by table 2.
- a compound listed in table 3 under “Drug 1 (PugChem ID)” can be used for the treatment of a disease or disorder treatable with a drug of the therapeutic class indicated under "T. Cat Drug2” and encoded by table 2.
- Clobetasol may be used for the treatment of a disease treatable with an antiinflamatory agent (therapeutic category "SOlB") or with a corticosteroid for systemic use (therapeutic category "H02").
- Spironolactone may be used for the treatment of a disease treatable with an androgen (therapeutic category "G03B").
- a compound according to the invention can be administered by various well known routes, including oral, rectal, intragastrical, intracranial and parenteral administration, e.g. intravenous, intramuscular, intranasal, intradermal, subcutaneous, and similar administration routes.
- parenteral administration and particular intravenous administration preferably by depot injection, is preferred.
- different pharmaceutical formulations are required and some of those may require that protective coatings are applied to the drug formulation to prevent degradation of a compound of the invention in, for example, the digestive tract.
- a compound of the invention is formulated as a syrup, an infusion or injection solution, a tablet, a capsule, a capslet, lozenge, a liposome, a suppository, a plaster, a band-aid, a retard capsule, a powder, or a slow release formulation.
- the diluent is water, a buffer, a buffered salt solution or a salt solution and the carrier preferably is selected from the group consisting of cocoa butter and vitebesole.
- Particular preferred pharmaceutical forms for the administration of a compound of the invention are forms suitable for i ⁇ jectionable use and include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the final solution or dispersion form must be sterile and fluid.
- such a solution or dispersion will include a solvent or dispersion medium, containing, for example, water-buffered aqueous solutions, e.g. biocompatible buffers, ethanol, polyol, such as glycerol, propylene glycol, polyethylene glycol, suitable mixtures thereof, surfactants or vegetable oils.
- a compound of the invention can also be formulated into liposomes, in particular for parenteral administration. Liposomes provide the advantage of increased half life in the circulation, if compared to the free drug and a prolonged more even release of the enclosed drug.
- Sterilization of infusion or injection solutions can be accomplished by any number of art recognized techniques including but not limited to addition of preservatives like anti-bacterial or anti-fungal agents, e.g. parabene, chlorobutanol, phenol, sorbic acid or thimersal. Further, isotonic agents, such as sugars or salts, in particular sodium chloride may be incorporated in infusion or injection solutions.
- preservatives like anti-bacterial or anti-fungal agents, e.g. parabene, chlorobutanol, phenol, sorbic acid or thimersal.
- isotonic agents such as sugars or salts, in particular sodium chloride may be incorporated in infusion or injection solutions.
- sterile injectable solutions containing one or several of the compounds of the invention is accomplished by incorporating the respective compound in the required amount in the appropriate solvent with various ingredients enumerated above as required followed by sterilization. To obtain a sterile powder the above solutions are vacuum-dried or freeze-dried as necessary.
- Preferred diluents of the present invention are water, physiological acceptable buffers, physiological acceptable buffer salt solutions or salt solutions.
- Preferred carriers are cocoa butter and vitebesole.
- Excipients which can be used with the various pharmaceutical forms of a compound of the invention can be chosen from the following non-limiting list: a) binders such as lactose, mannitol, crystalline sorbitol, dibasic phosphates, calcium phosphates, sugars, microcrystalline cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, polyvinyl pyrrolidone and the like; b) lubricants such as magnesium stearate, talc, calcium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, leucine, glycerids and sodium stearyl fumarates, c) disintegrants such as starches, croscaramellose, sodium methyl cellulose, agar, bentonite, alginic acid, carboxymethyl cellulose, polyvinyl pyrrolidone and the like.
- binders such as lactose, mannitol, crystalline sorb
- the dosage of a compound of the invention in the therapeutic or prophylactic use of the invention should be in the range of about 0.1 mg to about 1 g serum per kg body weight.
- a compound of the invention is administered to a subject in need thereof in an amount ranging from 1.0 to 500 mg/kg body weight, preferably ranging from 10 to 200 mg/kg body weight, preferably ranging from 50 to 150 mg/kg body weight, preferably ranging from 90 to 100 mg/kg body weight.
- the duration of therapy with a compound of the invention will vary, depending on the severity of the disease being treated and the condition and idiosyncratic response of each individual patient.
- the pharmaceutically effective amount of a given composition will also depend on the administration route. In general the required amount will be higher, if the administration is through the gastrointestinal tract; e.g.
- a compound of the invention will be administered in ranges of 50 mg to 1 g/kg body weight, preferably 100 mg to 500 mg/kg body weight, if rectal or intragastric administration is used and in ranges of 10 to 100 mg/kg body weight, if parenteral administration is used.
- a prophylactic administration of the biologically active blood serum or the pharmaceutical composition according to the invention may be possible.
- the respective compound of the invention is preferably administered in above outlined preferred and particular preferred doses on a daily basis. Preferably, between 0.1 mg to 1 g/kg body weight once a day, preferably 10 to 200 mg/kg body weight. This administration can be continued until the risk of developing the respective disorder has lessened. In most instances, however, a compound of the invention will be administered once a disease/disorder has been diagnosed. In these cases it is preferred that a first dose of a compound of the invention is administered one, two, three or four times daily. Preferably the administration is discontinued for one day, one week or one month and then repeated until the symptoms of the respective disease are no longer worsening or improving.
- the present invention provides in one aspect a method for identifying a novel medical indication of a pharmaceutically active compound comprising the steps: (a) extracting side-effects of a first pharmaceutically active compound from at least one database;
- the method of the invention further comprises the step
- step (d) determining a chemical similarity score which is the degree of structural similarity between the first and the second pharmaceutically active compound. It is further preferred that the method according to the invention further comprises the step (e) determining the probability that the second pharmaceutically active compound binds to the same therapeutic target protein as the first pharmaceutically active compound; wherein the probability is a function of the side-effect similarity score from step (c) and/or of the chemical similarity score from step (d).
- the method according to the invention further comprises the step (f) repeating steps (a) through (e) for a multiplicity of non-redundant pairs of pharmaceutically active compounds; wherein each pair comprises a respective first and second pharmaceutically active compound. It is further preferred that the method according to the invention further comprises the step
- step (g) if the probability determined in step (e) is greater than 20% preferably greater than 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, or 50% and most preferably greater than 25%, then: selecting the medical indication of the first pharmaceutically active compound as a novel medical indication for the second pharmaceutically active compound; and/or selecting the medical indication of the second pharmaceutically active compound as a novel medical indication for the first pharmaceutically active compound; Further preferred is the method of the invention, wherein in step (a) and/or (b), extracted side- effects that are synonymous and/or fall into a common classification class such as defined e.g. by the Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) or the International Classification of Primary Care (ICPC), are grouped and treated as one side-effect throughout the method.
- COSTART Coding Symbols for a Thesaurus of Adverse Reaction Terms
- ICPC International Classification of Primary Care
- the method of the invention wherein at least one parent side-effect from at least one ontology, for example from one described above, is assigned to each side-effect of the first and/or second pharmaceutical compound to provide an "is-a" relation which is preferably used to determine similarities between closely related side effects.
- the extracted side effects are expanded with concepts related to them by a "is-a" relation from an ontology such as COSTART, i.e. parents terms from the ontology are assigned to capture similarities between closely related side effects.
- an ontology such as COSTART
- parents terms from the ontology are assigned to capture similarities between closely related side effects.
- macrocytic anaemia is a parent term of megaloblastic anaemia and is, thus, automatically assigned to all drugs that have this side effect.
- step (c) is a similarity measure and preferably is a distance measure.
- the similarity measure used in the method according to the invention is the sum of all side-effects shared between the first and second pharmaceutically active compound.
- An example for the aforementioned preferred embodiment is provided in example 1 and figure IE.
- the similarity measure may also be selected from the group consisting of: a Cosine coefficient, a Dice coefficient, an Euclid coefficient, a Forbes coefficient, a Hamman coefficient, a Jaccard coefficient, a Kulczynski coefficient, a Manhattan coefficient, a Matching coefficient, a Pearson correlation, a Rogers-tanimoto coefficient, a Russell-rao coefficient, a Simpson coefficient, a Tanimoto coefficient and a Yule coefficient.
- each shared side-effect is weighted according to the frequency of its occurrence and/or according to the frequency with which the side-effect correlates with other side-effects.
- An example for this is given in figure 1C and ID and in the respective examples.
- the method of the invention wherein the weight used to account for the frequency of correlation is determined using a tree weighting algorithm, for example the Gerstein-Sonnhammer-Chothia algorithm (see for example also the examples and fig. 1C).
- the weight of the side-effect frequency is the negative logarithm of the side-effect's frequency of occurrence (see for example also the examples and fig. ID).
- the side-effect similarity score is normalized by determining what fraction of a multiplicity of pairs of pharmaceutically active compounds, each of which has randomized side effects, has a side-effect similarity score which is equal or greater than the side-effect similarity score of the first and the second pharmaceutically active compound. Further preferred is the method of the invention, wherein
- each pair of said multiplicity of pairs of pharmaceutically active compounds has the same respective number of side-effects than the first and the second pharmaceutically active compound;
- step (iii) random side effects are selected for each pharmaceutically active compound by replacing each original side effect with one side-effect that is randomly selected from a set of side effects with similar frequency of occurrence.
- the chemical similarity score in step (d) is a Tanimoto 2D chemical similarity score, a Tanimoto 3D chemical similarity score, or a Tversky index.
- the probability in step (e) is determined using a continuous or discontinuous probability function that has been derived from a reference dataset comprising pharmaceutically active compounds, their respective side-effects as well as their respective one or more therapeutic target proteins.
- a reference dataset comprising pharmaceutically active compounds, their respective side-effects as well as their respective one or more therapeutic target proteins.
- derived preferably refers to selecting a mathematical function, i.e. said probability function which preferably statistically correlates data comprised in said reference dataset of one pharmaceutically active compound to the data comprised in said reference dataset of a further pharmaceutically active compound.
- the probability function correlates the side-effect similarity score determined according to step (c) and/or the chemical similarity score determined according to step (d) of a pair of pharmaceutically active compounds in the reference set with the probability that said pair shares the same therapeutic target protein.
- the probability function is a sigmoid function.
- x is the side-effect similarity score
- y is the chemical similarity score
- H is a real number between 0.7 and 0.9, preferably 0.83;
- A is a real number between 0.01 and 0.03, preferably 0.0167;
- B is a real number between 50 and 60, preferably 55.507;
- C is a real number between -600 and -1000, preferably -810.16;
- D is a real number between -50 and -200, preferably -129.6;
- E is a real number between 400 and 600, preferably 455.6;
- F is a real number between 500 and 700, preferably 617.3;
- G is a real number between 0.1 and 0.8, preferably 0.415.
- the probability function is a discontinuous function derived from the fraction of drug pairs that share a target within intervals of side-effect similarity scores and chemical similarity scores.
- the side-effect similarity score in step (c) is the weighted sum of all side-effects shared between the first and second pharmaceutically active compound; wherein the chemical similarity score in step (d) is a Tanimoto 2D chemical similarity score and wherein the probability function is a sigmoid function.
- the invention also provides a computer program product stored on a computer readable storage medium comprising a computer-readable program code for causing a computer to carry out the method according to the invention.
- an apparatus for carrying out the method according to the invention is also comprised.
- a data processing system e.g. a personal computer, comprising a memory device, an operating system and the computer program product according to the invention which is loaded into the memory device of said data processing system and wherein the data processing system is capable of carrying out the method according to the invention.
- the invention provides the use of a pharmaceutically active compound for which a novel medical indication has been identified according to the method of of the invention for the prevention or treatment of the respective novel medical indication that has been identified according to the method of the invention.
- Fig. 1 Flowchart of the method.
- A) Terms for side effects are extracted from the package inserts, B) subjected to ontological annotation in the UMLS ontology and then weighted for C) cross-correlation and D) frequency.
- macrocytic anaemia (E) is a parent term of megaloblastic anaemia (A) and is thus automatically assigned to all drugs that have this side effect.
- A) a raw side-effect similarity score is derived and F) normalized.
- Fig. 2 Breakdown of drug pairs predicted to share a target.
- A) The predicted 2903 drug pairs were subjected to consecutive filtering for a number of properties, leaving 754 pairs that imply unexpected drug-target relations.
- B) The subset of pairs and implied predictions that are predominantly based on side-effect similarity (requiring an additional stringent p-value ⁇ 0.1) was used for network analysis (Fig. 3).
- Fig. 3 Drug network based on likelihoods for having common protein targets.
- a drug subnetwork around the anti-ulcer drug Rabeprazole and other 15 experimentally confirmed predictions are shown around the network.
- Fig. 4 Novel drug— target relationships.
- the line delimits the area used to construct the network in Fig. 3 with shared target probability >25% and side-effect p-value ⁇ 0.1.
- Drug pairs that have been experimentally confirmed to share a target are denoted by black and grey dots according to Ki value.
- Fig. 5 Drug-protein interactions of reference set.
- Our reference set was derived from the MATADOR database (Manually Annotated Targets and Drugs Online Resource,(i)), DrugBank (2) and the PDSP Ki database (3). Metabolizing enzymes and proteins with unspecific drug binding were excluded from the reference set. From the PDSP Ki database, we only included interactions with an inhibition constant below lO ⁇ M. The number of drugs with annotated targets in MATADOR, DrugBank and the PDSP Ki database are 381, 462 and 148, respectively. The contributions of drug-protein interactions of the three databases to our reference are shown in a Venn diagram. The different databases treat interactions with protein groups such as complexes and families of proteins differently.
- Fig. 6 Benchmarking of target prediction methods. Three probabilistic methods that evaluate the probability of two drugs to share a target were compared. A) The first method is based on the comparison of side effects information of drugs (SE). The dotted line represents 50% probability of sharing targets at which the side-effect similarity p-value is 0.0045. B) The second method uses the information provided by the chemical similarity between drugs (2D) and the third method combines both individual predictors (SE_2D). Both individual methods show a clear correlation between similarity and the probability of sharing a common target. In our reference set, a Tanimoto 2D similarity score of 0.85 implies a 74% chance of sharing a target.
- Fig. 7 The number of drug pairs falsely predicted to share targets depends on the number of side effects of the drugs involved.
- the number of drugs that do not share targets but are predicted to share a target with the given drug with at least 25% probability is calculated and averaged over a sliding window of 11 drugs.
- Drug pairs involving at least one drug with less than 7 side effects produce relatively many false positives and are thus discarded for prediction purposes.
- Our model employs small contributions of many side effects towards overall side effect similarity. Thus, very low numbers of side effects do not provide sufficient information for a reliable prediction.
- Fig. 8 Breakdown of drug pairs predicted to share targets in different probability intervals. Drug pairs with less than 25% probability of sharing targets (A) are contrasted with those in various probability intervals between 25% and 100% (B). C) Subset of (B) with the additional requirement of a side-effect similarity pvalue lower than 0.1. The type of drug pair (see boxed inset) is indicated. In the bar graph the type of drug pair is ordered from top to bottom as indicated in the boxed inset.
- Similarity of protein targets correlates with probability of binding the same ligand.
- Fig. 10 Extension of Fig. 4 in main manuscript with details of experimental validation of 20 predicted drug pairs in the network.
- Predicted targets for drugs from the 20 drug pairs candidates in the network were tested in in vitro binding assays at 50 ⁇ M.
- Ki inhibition constant
- Prob. is the probability of sharing a target and nh refers to the Hill coefficient of the concentration-curves.
- Drug pairs sharing targets in the reference set were grouped in intervals by their probability of sharing targets as predicted by the combination of both side effect similarity and chemical similarity (A), side effect similarity alone (B) or chemical similarity alone (C).
- A side effect similarity and chemical similarity
- B side effect similarity alone
- C chemical similarity alone
- the average number of targets that are not shared (as indicated) and the average numbers of targets , that are shared (as indicated) were calculated within the intervals. Linear regression reveals that the probability of sharing a target correlates negatively with the number of targets that is not shared by the drug pair. This correlation is not observed when the number of targets shared for the drug pair is compared.
- ⁇ The square of the Pearson product-moment correlation coefficient is shown ( ⁇ ) along with the statistical significance of the correlation as assessed by 1000 randomizations of the drug pairs. The error bars indicate the standard deviation of the data.
- Fig. 12 Two-dimensional histogram representing the probabilities that two drugs share the same target as a function of side effect similarity p-value and chemical similarity.
- Table 1 FDA-approved drugs analyzed in this work. ID is the drug PubChem identifier. (Stereoisomers were merged into one compound.) Table 2 List of therapeutic categories.
- Table 3 Excerpt of the list of the 1018 drugs pairs with a probability (Prob) of sharing a target higher than 25% and side effect similarity p-value (SE) below 0.1.
- the Tanimoto coefficient of the drugs of the pairs (2D) is also given.
- Drug pairs are classified into five groups (1-5) according to the main text ( Figure 2 and Figure 3) whereby the respective groups are subtracted from the total 1018 prediction in the following order to arrive at the unexpected findings (group 5). From the total 1018 drug pairs, we first subtracted those drug pairs that are known to share targets (group 1); in this group 57 drug pairs with high chemical similarity can be found, as the chemical similarity filter was not applied to them.
- Classification System ATC (comprised in table 2), additional indications which are not covered included in table 2 can be found.
- the compounds ethionamide, zaleplon, zopiclone and doxorubicin can be used as antihistamines.
- these compounds can be used to inhibit the release or action of histamine.
- Histamine can be quantified using, for example, an ELISA assay and anti-histamine specific antibodies.
- Drugs that are part of the reference set and that imply a known human target are marked with an asterisk.
- the majority of the drugs that are not part of the reference set are drugs directed against non-human proteins (for example, antibiotics), but there is also a small number of drugs with as yet unknown target.
- drugs directed against human were retrievable from the resources used, and some drugs directed against human were not annotated in the reference sets (for example, endogenous compounds).
- the list contains a few drug pairs that are labelled as predictions (groups 2-5) although they are known to share a target (which underlines the predictive power of the approach).
- Example 1 Quantification and normalization of side-effect similarities
- UMLS Unified Medical Language System
- Fig. 3 we focused on those areas in the network that contain drugs with human targets, which belong to different therapeutic categories.
- Rabeprazole a proton pump inhibitor.
- five drug pairs are predicted to share targets with a probability in the range of 30-75%; four of them involve Rabeprazole.
- Fig. 4 We validated all our predictions in this subnetwork both with in vitro and cell assays (Fig. 4). It appears that Rabeprazol binds both the dopamine receptor DRD3 with an antagonist activity and, with lower affinity, the serotonin receptor HTRlD. We could not detect binding to the serotonin transporter SLC6A4 (Fig. 3B).
- the nervous system drugs Pergolide, Paroxetine and Fluoxetine are known to share two of the three targets above (Fig. 3B), while Zolmitriptan only seems to bind to its primary target serotonin receptor HTRlD that it shares with Rabeprazol (Fig. 3B).
- Donepezil's primary targets are cholinesterases. We show here that it also binds to serotonin transporter SLC6A4 in vitro and inhibits it in cell assays; this might explain Donepezil's strong side-effect similarity with Venlafaxin (Fig. 3B).
- the sharing of side effects of the proton pump inhibitor Rabeprazole revealed two nervous system off-targets with affinities (Fig.
- the reference set is composed of 502 drugs approved by the FDA (Food and Drug Administration) with 4857 associated drug-protein interactions.
- the drug- protein interactions were extracted from the MATADOR database (1), DrugBank (2) and the PDSP Ki database (3) (K. binding affinity lower than 10 ⁇ M).
- the different contributions of drug-target interactions of the databases are shown in a Venn diagram (Fig. 5).
- a target as a protein that binds physically to the drug and might be responsible of the drug mechanism of action.
- metabolizing enzymes and unspecific protein binders like albumin also bind drugs, they cannot generally be associated with the mechanism of action and they were therefore excluded from our reference set.
- the side effect and indication area sections of drug labels were extracted and searched for known terms of side effects. 1443 concepts from UMLS ontology were found by text mining. In order to avoid spurious hits resulting from the description of the drug's purpose within the side effect section, concepts found in the indication area section were masked and discarded from the concepts extracted from the side effect section.
- Drug labels were assigned to chemical compounds by matching of drug synonyms. Labels for combinations of drugs were discarded during the name mapping and by manual inspection of labels that contain the names of other drugs in the side-effect section. In some cases, groups of closely related drugs, such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), are listed together on one label. These labels require manual intervention, as our the text-mining approach assigns all mentioned side effects to all drugs of the label although some of the side effect might only be relevant for some of the drugs. Therefore, these labels were manually annotated to assign the listed side effects to the specific drugs.
- NSAIDs Nonsteroidal Anti-Inflammatory Drugs
- the weighting scheme consists of two parts, a rareness weight and a correlation weight.
- the rareness weight for a side effect, ⁇ is defined as the negative logarithm of the side-effect frequency fi. (This frequency refers to the fraction of drug labels that feature a certain side effect, not the relative occurrence of the side effect in patients).
- the correlation of side effects was determined by clustering all side effects according to their assigned drugs using a Tanimoto/Jacquard score to compute a distance matrix: The distance between two drugs was calculated by dividing the number of drugs that feature both side effects by the number of drugs that have either side effect associated.
- the Gerstein-Sonnhammer- Chothia algorithm (7) was used to compute weights based on a hierarchal clustering with the aforementioned distance matrix (S).
- a raw score for the side-effect similarity of a drug-drug pair was calculated by summing the product of the weights over all shared concepts. This raw score was converted into a p-value by generating 10,000 drug pairs in which each side effect has been replaced by a randomly chosen side effect of similar frequency. For each side effect, a set of neighbours was assembled from the 100 side effects that are closest in frequency. This set was then extended to include all side effects of equal rareness.
- the open-source Chemistry Development Kit (P) was used to calculate chemical fingerprints and the commonly used Tanimoto 2D chemical similarity scores (10, 11).
- Example 11 Combining 2D and side effect similarity for target prediction.
- Drug pairs were scored by their probability of sharing targets based on a function of side- effect similarity and 2D similarity. To this end, we distributed drug pairs from the reference set in a two-dimensional histogram (Figure 12). In the first dimension, drug pairs were distributed using logarithmic percentiles of their ranked side effect similarity p-values, and in the second dimension, they were distributed using percentiles or their ranked chemical similarity. Equal similarity values were assigned to the same percentile.
- the fraction of drug pairs that share a target is computed as a function of the natural logarithm of the average side effect similarity p-value (JC in the following equations) and average chemical similarity (2D Tanimoto coefficient, y) within the cell.
- JC average side effect similarity
- 2D Tanimoto coefficient, y average chemical similarity
- PSE,2D represents the probability of sharing the same target for a drug pair with a given side effect similarity p-value and chemical similarity.
- P2D is the probability of sharing the same target as a function of chemical similarity of drug pairs only.
- the function used to model the probability of sharing the same target as predicted using only side effect similarity information is the following:
- PSE is the probability of sharing the same target for a drug pair predicted using only side effect similarity information.
- Example 12 Quantifying the impact of target similarity.
- Ki values less or equal to 10 ⁇ M were considered as binding, whereas higher Ki values were considered as non-binding.
- Normalized bitscores of 0 in Fig. 9A were caused by low-similarity alignments that are not reported. Protein- protein pairs were sorted by normalized bitscores and binned (14).
- the company Cerep performed the enzymatic assay for the prostaglandinendoperoxide synthase 2 (COX2, 777-2hr) and binding assays to the dopamine receptor type 3 (D3h, 803-3h), the serotonin transporter (5-HT transporter, 808-Uh), the serotonin receptor ID (5-HTID, 808- ldc), the alpha-2 adrenergic receptor (alpha2A, 802- IbAh), the alpha- 1 adrenergic receptor (alphal, non-selective, 802-la), the beta-1 adrenergic receptor (betal, 802-2ah), the peripheral- type benzodiazepine receptor (BZD, 852), the calcium-activated potassium channel (SKCa, 863- 3), the dopamine receptor type 1 (Dl, 803-lh), the dopamine receptor 2 (D2S,803-2h), the GABA receptor (GABA, non-selective,
- L concentration of radioligand in the assay
- KD affinity of the radioligand for the receptor.
- the specificity of the in vitro binding assay was controlled by using negative controls at 50 ⁇ M. For assays where our own tested candidates did not give negative results (Fig. 10), we ordered tests against compounds we did not expect to bind to verify the specificity. Those compounds are Mafenide on the 808-Uh (5-HT transporter) and 808- ldc (5-HTID) assays and Aspirin on the 805-Ih (Hl) assay.
- Example 14 Cell assays. The agonist and antagonist responses of all drugs that showed binding activity (inhibitory activity of the reference compound binding activity) above 40% were tested by Cerep at 50 ⁇ M using the following assays: Donepezil: serotonin uptake assay (710); Ketoconazole: serotonin receptor 2C (agonist effect: 722-13a, antagonist effect: 722-13b); Fluoxetine, Rabeprazole and Paroxetine: dopamine receptor 3 (agonist effect: 758-19a, antagonist effect: 758-19b); Zaleplon, Disopyramide, Clomiphene and Acitretin: histamine Hl receptor (agonist effect: 721 -7a, antagonist effect: 721 -7b).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un procédé d'identification d'une nouvelle indication médicale d'un composé pharmaceutiquement actif. L'invention propose en outre de nouvelles indications médicales pour plusieurs composés pharmaceutiquement actifs. En particulier, elle propose des composés pour la prévention et le traitement d'une maladie ou d'un trouble qui peuvent être traités avec un inhibiteur de la réabsorption de la sérotonine-norépinéphrine (SNRI), un antagoniste des récepteurs de la sérotonine, un estazolam, un antagoniste des récepteurs de la dopamine, un agoniste des récepteurs de la dopamine, un agent de blocage des canaux de calcium de type L, un modulateur sélectif des récepteurs d'oestrogène (SERM) et un antihistaminique. L'invention propose également un composé pharmaceutiquement actif pour la prévention ou le traitement de la tachycardie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4329208P | 2008-04-08 | 2008-04-08 | |
US61/043,292 | 2008-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009124755A1 true WO2009124755A1 (fr) | 2009-10-15 |
Family
ID=40791404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/002620 WO2009124755A1 (fr) | 2008-04-08 | 2009-04-08 | Composés à nouvelles utilisations médicales et procédés d'identification de ces composés |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009124755A1 (fr) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
CN103860561A (zh) * | 2014-04-08 | 2014-06-18 | 青岛大学医学院附属医院 | 一种防治乳腺癌的药物组合物及其应用 |
US8765758B2 (en) | 2009-12-17 | 2014-07-01 | Eye Therapies Llc | Compositions and methods for eye whitening |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
WO2015150299A3 (fr) * | 2014-04-01 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Traitement de troubles métaboliques chez les équidés |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CN106470994A (zh) * | 2014-08-27 | 2017-03-01 | 豪夫迈·罗氏有限公司 | 用于治疗cns疾病的取代的吡嗪并[2,1‑a]异喹啉衍生物 |
US9585893B2 (en) | 2011-02-23 | 2017-03-07 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
WO2017040778A1 (fr) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Composé thérapeutique contre la douleur et sa synthèse |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
WO2018208633A1 (fr) * | 2017-05-07 | 2018-11-15 | China Medical University | Méthodes et compositions pour traiter le syndrome de sevrage |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10357487B2 (en) * | 2015-12-03 | 2019-07-23 | Sidney J. Goldfarb | Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
US10603300B2 (en) | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
US10617666B2 (en) | 2013-12-17 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN115515578A (zh) * | 2020-05-07 | 2022-12-23 | 诺罗瑞韦有限公司 | 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11596600B2 (en) | 2008-08-01 | 2023-03-07 | Eye Therapies, Llc | Vasoconstriction compositions and methods of use |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
-
2009
- 2009-04-08 WO PCT/EP2009/002620 patent/WO2009124755A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
CAMPILLOS M ET AL: "Drug target identification using side-effect similarity", SCIENCE 20080711 US, vol. 321, no. 5886, 11 July 2008 (2008-07-11), pages 263 - 266, XP002534673, ISSN: 0036-8075 1095-9203 * |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11596600B2 (en) | 2008-08-01 | 2023-03-07 | Eye Therapies, Llc | Vasoconstriction compositions and methods of use |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US11833245B2 (en) | 2008-08-01 | 2023-12-05 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
US8765758B2 (en) | 2009-12-17 | 2014-07-01 | Eye Therapies Llc | Compositions and methods for eye whitening |
US9259425B2 (en) | 2009-12-17 | 2016-02-16 | Eye Therapies Llc | Compositions and methods for eye whitening |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US9585893B2 (en) | 2011-02-23 | 2017-03-07 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10639281B2 (en) | 2013-08-12 | 2020-05-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10772871B2 (en) | 2013-10-07 | 2020-09-15 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
US10987342B2 (en) | 2013-10-07 | 2021-04-27 | Teikoku Pharma Usa, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
US10874642B2 (en) | 2013-10-07 | 2020-12-29 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10792254B2 (en) | 2013-12-17 | 2020-10-06 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10617666B2 (en) | 2013-12-17 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US11896574B2 (en) | 2013-12-17 | 2024-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US11433045B2 (en) | 2014-01-23 | 2022-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
US10603300B2 (en) | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
US11535614B2 (en) | 2014-02-03 | 2022-12-27 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10807980B2 (en) | 2014-02-03 | 2020-10-20 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9624217B2 (en) | 2014-02-03 | 2017-04-18 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10399976B2 (en) | 2014-02-03 | 2019-09-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10047085B2 (en) | 2014-02-03 | 2018-08-14 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10688116B2 (en) | 2014-04-01 | 2020-06-23 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
WO2015150299A3 (fr) * | 2014-04-01 | 2015-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Traitement de troubles métaboliques chez les équidés |
CN103860561A (zh) * | 2014-04-08 | 2014-06-18 | 青岛大学医学院附属医院 | 一种防治乳腺癌的药物组合物及其应用 |
CN103860561B (zh) * | 2014-04-08 | 2015-11-18 | 青岛大学医学院附属医院 | 一种防治乳腺癌的药物组合物及其应用 |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
CN106470994A (zh) * | 2014-08-27 | 2017-03-01 | 豪夫迈·罗氏有限公司 | 用于治疗cns疾病的取代的吡嗪并[2,1‑a]异喹啉衍生物 |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
US10087184B2 (en) | 2014-10-14 | 2018-10-02 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of RORγ |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US11001583B2 (en) | 2014-11-05 | 2021-05-11 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10829448B2 (en) | 2015-08-05 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Substituted benzoimidazoles as modulators of ROR-γ |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
WO2017040778A1 (fr) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Composé thérapeutique contre la douleur et sa synthèse |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US10357487B2 (en) * | 2015-12-03 | 2019-07-23 | Sidney J. Goldfarb | Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2018208633A1 (fr) * | 2017-05-07 | 2018-11-15 | China Medical University | Méthodes et compositions pour traiter le syndrome de sevrage |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
CN115515578A (zh) * | 2020-05-07 | 2022-12-23 | 诺罗瑞韦有限公司 | 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009124755A1 (fr) | Composés à nouvelles utilisations médicales et procédés d'identification de ces composés | |
Richards et al. | Pharmacologic treatment of cannabinoid hyperemesis syndrome: a systematic review | |
Ahmed et al. | Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review | |
Seidel et al. | Antipsychotics for acute and chronic pain in adults | |
Usmani et al. | Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease | |
Lipton et al. | Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study | |
Pringsheim et al. | Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders | |
Bell‐Syer et al. | Oral treatments for fungal infections of the skin of the foot | |
Kaminski et al. | Antidepressants for the treatment of abdominal pain‐related functional gastrointestinal disorders in children and adolescents | |
Pollack et al. | Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial | |
Nolan et al. | Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database | |
Geddes et al. | Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression | |
Guaiana et al. | Amitriptyline for depression | |
Tang et al. | Personality change during depression treatment: a placebo-controlled trial | |
Flowers et al. | Co‐enzyme Q10 supplementation for the primary prevention of cardiovascular disease | |
Krystal et al. | Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms | |
Racz et al. | Association between serotonin syndrome and second‐generation antipsychotics via pharmacological target‐adverse event analysis | |
Sharma et al. | H1‐antihistamines for chronic spontaneous urticaria | |
Cipriani et al. | Haloperidol alone or in combination for acute mania | |
Kamm | The complexity of drug development for irritable bowel syndrome | |
Guo et al. | Hawthorn extract for treating chronic heart failure | |
Gendle et al. | Oral administration of 5‐hydroxytryptophan (5‐HTP) impairs decision making under ambiguity but not under risk: evidence from the Iowa Gambling Task | |
Jones et al. | Emerging 5-HT receptor antagonists for the treatment of Schizophrenia | |
Soares et al. | Penfluridol for schizophrenia | |
Shi et al. | Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09730882 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09730882 Country of ref document: EP Kind code of ref document: A1 |